Trials / Recruiting
RecruitingNCT05985655
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
- Triple Negative Breast Cancer (TNBC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTAEXS617 | Administered as specified in the treatment arm. |
| DRUG | SoC | Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm. |
Timeline
- Start date
- 2023-07-06
- Primary completion
- 2028-01-01
- Completion
- 2028-05-01
- First posted
- 2023-08-14
- Last updated
- 2026-02-12
Locations
12 sites across 3 countries: United States, Belgium, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05985655. Inclusion in this directory is not an endorsement.